Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Brian G. Feagan, William J. Sandborn, Geert D’Haens, +19

The Lancet

InflammationRheumatologyPlacebo-controlled Phase 2Autoimmune DiseaseImmunology +6

Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites

Bojan Lalovic, Evan D. Kharasch, Danny D. Shen

Clinical Pharmacology & Therapeutics

QUANTITATIVE CONTRIBUTION OF CYP2D6 AND CYP3A TO OXYCODONE METABOLISM IN HUMAN LIVER AND INTESTINAL MICROSOMES

Bojan Lalovic, Brian Phillips, Linda L. Risler, +2

Drug Metabolism and Disposition

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

James G. Krueger, Laura K. Ferris, Alan Menter, +10

Journal of Allergy and Clinical Immunology

ImmunologyClinical TrialsBiomarker ResultsClinical DermatologyPlacebo-controlled Trial +6

Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab

Sudha Visvanathan, Patrick Baum, Richard Vinisko, +11

Journal of Allergy and Clinical Immunology

Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults

Ishani Landry, Kenya Nakai, Jim Ferry, +4

Clinical Pharmacology in Drug Development

Sleep DisordersPharmacotherapyExperimental PharmacologyPharmacodynamic ModelingLemborexant Pharmacokinetics +14

Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia

Ryan M. McAdams, Daniel Pak, Bojan Lalovic, +2

Anesthesiology Research and Practice

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder

Bojan Lalovic, Oneeb Majid, Jagadeesh Aluri, +3

The Journal of Clinical Pharmacology

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant

Ishani Landry, Jagadeesh Aluri, Kenya Nakai, +8

Clinical Pharmacology in Drug Development

Risk‐Based Pharmacokinetic and Drug–Drug Interaction Characterization of Antibody–Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective

Chunze Li, Rajeev Menon, Markus Walles, +15

Clinical Pharmacology & Therapeutics

Drug TargetImmunologyImmunotherapyUnconjugated PayloadPharmacodynamic Modeling +17